NASDAQ:ATXIAvenue Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avenue Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.76 +0.01 (+0.10 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$9.36Now: $9.76▼$9.9350-Day Range$9.70MA: $10.73▼$11.4752-Week Range$4.96Now: $9.76▼$11.83Volume36,100 shsAverage Volume64,737 shsMarket Capitalization$162.83 millionP/E RatioN/ADividend YieldN/ABeta0.2 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAvenue Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Avenue Therapeutics has a potential upside of 33.2% from its current price of $9.76.Amount of Analyst CoverageAvenue Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesAvenue Therapeutics has received 136 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAvenue Therapeutics has received 176 “underperform” votes. (Add your “underperform” vote.)Community SentimentAvenue Therapeutics has received 56.41% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote “Outperform” if you believe ATXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 11.78% of the stock of Avenue Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avenue Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is -10.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is -10.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 23.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATXI Previous Symbol CUSIPN/A CIK1644963 Webwww.avenuetx.com Phone781-652-4500Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book23.80Profitability EPS (Most Recent Fiscal Year)($1.65) Net Income$-25,910,000.00 Net MarginsN/A Return on Equity-165.26% Return on Assets-140.65%Miscellaneous Employees6 Outstanding Shares16,683,000Market Cap$162.83 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable NASDAQ:ATXI Rates by TradingView Receive ATXI News and Ratings via Email Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions How has Avenue Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Avenue Therapeutics' stock was trading at $7.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATXI shares have increased by 31.2% and is now trading at $9.76. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Avenue Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avenue Therapeutics. When is Avenue Therapeutics' next earnings date? Avenue Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Avenue Therapeutics. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics Inc (NASDAQ:ATXI) issued its quarterly earnings results on Monday, May, 11th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.09. View Avenue Therapeutics' earnings history. What price target have analysts set for ATXI? 1 brokerages have issued 12-month price objectives for Avenue Therapeutics' shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate Avenue Therapeutics' share price to reach $13.00 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View analysts' price targets for Avenue Therapeutics. Has Avenue Therapeutics been receiving favorable news coverage? Media stories about ATXI stock have trended very negative this week, InfoTrie reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Avenue Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Avenue Therapeutics. Are investors shorting Avenue Therapeutics? Avenue Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 49,300 shares, an increase of 31.1% from the June 15th total of 37,600 shares. Based on an average daily volume of 49,900 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.8% of the company's stock are sold short. View Avenue Therapeutics' Current Options Chain. Who are some of Avenue Therapeutics' key competitors? Some companies that are related to Avenue Therapeutics include Provention Bio (PRVB), Cue Biopharma (CUE), Vanda Pharmaceuticals (VNDA), Aprea Therapeutics (APRE), Stemline Therapeutics (STML), RAPT Therapeutics (RAPT), Radius Health (RDUS), Passage Bio (KROS), Trillium Therapeutics (TRIL), Basilea Pharmaceutica (BPMUF), Collegium Pharmaceutical (COLL), Atreca (BCEL), Molecular Templates (MTEM), AnaptysBio (ANAB) and Ardelyx (ARDX). View all competitors. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avenue Therapeutics investors own include CytomX Therapeutics (CTMX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Agile Therapeutics (AGRX), Allena Pharmaceuticals (ALNA), Aquestive Therapeutics (AQST), Actinium Pharmaceuticals (ATNM), Cidara Therapeutics (CDTX) and Crispr Therapeutics (CRSP). Who are Avenue Therapeutics' key executives? Avenue Therapeutics' management team includes the following people: Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 64)Dr. Lucy Lu, Pres, CEO & Director (Age 44)Mr. Joseph Walter Vazzano, CFO, Principal Financial Officer & Company Sec. (Age 35)Dr. Scott A. Reines, Interim Chief Medical Officer (Age 72) When did Avenue Therapeutics IPO? (ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager. What is Avenue Therapeutics' stock symbol? Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI." How do I buy shares of Avenue Therapeutics? Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Avenue Therapeutics' stock price today? One share of ATXI stock can currently be purchased for approximately $9.76. How big of a company is Avenue Therapeutics? Avenue Therapeutics has a market capitalization of $162.83 million. The company earns $-25,910,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Avenue Therapeutics employs 6 workers across the globe. What is Avenue Therapeutics' official website? The official website for Avenue Therapeutics is www.avenuetx.com. How can I contact Avenue Therapeutics? Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
